Is CervoMed Inc halal to invest in?

According to Musaffa's Shariah screening methodology, CervoMed Inc (CRVO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is CervoMed Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes CervoMed Inc using these criteria to determine its compliance status.

Can Muslims buy shares of CervoMed Inc?

Muslim investors may consider investing in CervoMed Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is CervoMed Inc classified as NOT HALAL?

Musaffa determines the Shariah status of CervoMed Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for CervoMed Inc updated?

The Shariah compliance status of CervoMed Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like CervoMed Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of CervoMed Inc?

You can check the latest Shariah compliance status of CervoMed Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

CRVO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 16, 2026

Report Source: 2025 Annual Report

CervoMed Inc. Stock Analysis CRVO

United States Health Care Nano Cap Report: 2025 Annual

CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Key Statistics of CervoMed Inc (CRVO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$3.35$3.74

Today's Open

$3.74

Volume

119.64K

P/E Ratio (TTM)

52 Week Range

$3.35$13.13

Market Cap

34.54M

Avg. Volume

43.80K

Dividend Yield

Financial Metrics & Statements of CervoMed Inc (CRVO)

FAQ's for CervoMed Inc (CRVO)

According to Musaffa’s Shariah screening methodology, CervoMed Inc (CRVO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.